Gynaecologic Oncology

The Department of Gynecologic Oncology currently has three wards, 132 open beds, more than 50,000 outpatient visits per year, more than 5,000 operations per year, including more than 1,000 operations for malignant tumors, more than 3,000 chemotherapy cycles per year, and more than 1,000 cycles of targeted therapy and immunotherapy. Centered on common malignant tumors, the Department of Gynecologic Oncology has formed specialized teams focusing on ovarian cancer, endometrial cancer, and cervical cancer, and has an MDT team for collaboration inside and outside the hospital in gynecologic malignancies. It provides patients with “one-stop” comprehensive oncology diagnosis and treatment and precision therapy, including surgery, chemotherapy, targeted therapy, immunotherapy, fertility preservation, and tumor genetic counseling; focuses on major gynecologic oncology diseases and cutting-edge scientific questions in conducting various basic and clinical studies; and has achieved rapid development in medicine, education, and research, forming distinctive disciplinary characteristics and strengths. Recently, with the support of the Shanghai Soong Ching Ling Foundation’s “Yu Ai Tong Xing” Special Fund for Gynecologic Oncology, initiated by Professor Wang Yu, and the “Leading Goose Program” for Caring for Women, the Department of Gynecologic Oncology has devoted itself to establishing and promoting a standardized full-cycle diagnosis and treatment system for ovarian cancer, with its services extending to more than 300 medical institutions in the Yangtze River Delta region.

The department has more than 30 clinical physicians; those with associate-senior or higher professional titles account for 40%, and those with doctoral degrees account for approximately 70%; among them are 12 chief physicians, 5 professors, 3 associate professors, 7 doctoral supervisors, and 2 master’s supervisors. The department includes experts receiving special allowances from the State Council, Shanghai leading talents, outstanding academic leaders in Shanghai, and Shanghai Science and Technology Rising Stars; many have been selected for talent programs such as the Shanghai “Medical Garden Rising Stars” Outstanding Young Physician Training Program, Shanghai “Medical Garden Rising Stars” Young Medical Talents program, and the Shanghai Municipal Science and Technology Commission’s Yangfan (Sailing) Program. The research project led by Professor Wang Yu, “Innovation in and Mechanistic Research on Key Diagnostic and Treatment Technologies and Strategies for Metastatic Ovarian Cancer,” received the First Prize of the 2022 Shanghai Medical Science and Technology Awards. The research project led by Professor Wan Xiaoping, “New Strategies for Fertility-Preserving Treatment of Endometrial Cancer Based on New Mechanisms of Disease Onset,” received the Third Prize of the 2022 Chinese Medical Science and Technology Award. Professor Wang Wei leads one subproject of the National Key Research and Development Program of the Ministry of Science and Technology.

The department currently has 16 National Natural Science Foundation of China projects under way, 8 projects of the Shanghai Municipal Commission of Science and Technology, and 2 projects of the Shanghai Municipal Health Commission; it leads 2 Shanghai Shenkang clinical multicenter research projects, with total funding exceeding RMB 10 million. It conducts 10 domestic and international GCP research projects on advanced or recurrent ovarian cancer, endometrial cancer, and cervical cancer. In the past three years, it has published 100 SCI papers, with a cumulative impact factor exceeding 500.